•Reaffirms 2021 Full Year Forecast for Revenues and Profit GAITHERSBURG, Md., July 29, 2021-Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the second quarter ended June 30, 2021. Our second quarter performance demonstrates the strength of our strategy and diversified business model, said Robert G. Kramer, president and chief executive officer of Emergent BioSolutions. Through continued investment and innovation, we will play an important role in helping deliver solutions to the public health threats we face. We are proud to be resuming production of COVID-19 vaccine batches following additional reviews and collaboration with the Food and Drug Administration and our manufacturing partner.
Emergent BioSolutions Reports Financial Results For Second Quarter 2021
teletrader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from teletrader.com Daily Mail and Mail on Sunday newspapers.
构建与湾区城市定位相匹配的交通体系 把好事办好贯穿到交通建设管理全过程_新闻频道_中山网
zsnews.cn - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from zsnews.cn Daily Mail and Mail on Sunday newspapers.
Trung Quốc Bắt Đầu Thử Nghiệm Quy Mô Lớn internet Tương Lai
tin247.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tin247.com Daily Mail and Mail on Sunday newspapers.
DFnet and ClinConsent Join Forces to Meet Growing Demand for Patient-Centric eConsent Solutions
Share Article SEATTLE (PRWEB) April 13, 2021 DF/Net Research, Inc. (DFnet), a trusted leader in clinical data management solutions, today announced its partnership with ClinConsent, LLC. ClinConsent is a leading electronic informed consent (eIC) software provider. This partnership will further extend DFnet s suite of clinical data management solutions. At DFnet, we are proud to help researchers move science forward Lisa Ondrejcek, founder of DFnet, shares. The possibilities of electronic informed consent (eIC) are not only a step forward for traditional clinical research, but critical in the evolving virtual clinical trial landscape. We are thrilled to partner with ClinConsent to add this trusted, patient-centric consent solution to the DFnet roster.